Seeking Alpha

Akorn to buy Hi-Tech Pharmacal for $640M

  • Akorn (AKRX) has agreed to pay $640M to acquire Hi-Tech Pharmacal (HITK), which specializes in difficult-to-manufacture liquid and semi-solid dosage forms of drugs.
  • The offer of $43.50 a share represents a premium of 23.5% to Hi-Tech's closing price of $35.21 yesterday.
  • The combined company is expected to generate annual revenues of over $500M, with the deal expected to add to Akorn's adjusted EPS immediately after closing. The company expects to achieve $15-20M in annual run-rate synergies within 12 months after that.
  • Hi-Tech provides oral solutions and suspensions, topical ointments and creams, nasal sprays, otics, sterile ophthalmics, and sterile ointment and gels.
  • Hi-Tech's shares are suspended until 7:30 ET, while those of Akorn are +0.7%. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs